BIFRF (Biofrontera AG) Total Equity: $19.76 Mil (As of Mar. 2026)


BIFRF Biofrontera AG BIFRF
58 GF Score
Price $22.68
GF Value $31.34
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Total Equity?

Biofrontera AG BIFRF 58 Total Equity is $19.76 Mil as of Mar. 2026. GuruFocus rates BIFRF with a GF Score™ of 58/100 and a GF Value™ of $31.34. The stock has 4 warning signs investors should review.

Biofrontera AG's total equity for the quarter that ended in Mar. 2026 was $19.76 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Biofrontera AG Total Equity Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG Total Equity Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.89 21.54 21.79 19.75 17.45

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.13 17.47 17.37 17.45 19.76
BIFRF
58GF Score
Biofrontera AG BIFRF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Biofrontera AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=24.172-6.719
=17.45

Biofrontera AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=26.286-6.521
=19.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $19.76 Mil mean?
Biofrontera AG (BIFRF) has a Total Equity of $19.76 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Biofrontera AG and its competitors.
Is Biofrontera AG's Total Equity too high?
Biofrontera AG's current Total Equity is $19.76 Mil. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Total Equity compare to ZTS and UTHR?
Biofrontera AG's Total Equity of $19.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Biofrontera AG and its competitors. Biofrontera AG's current Total Equity is $19.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current Total Equity of $19.76 Mil. The stock's GF Value™ is $31.34, compared to a current price of $22.68 — trading 27.6% below its estimated fair value. The current Total Equity is $19.76 Mil. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current Total Equity is $19.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (BIFRF) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.

Key valuation signals for BIFRF:

  • Total Equity: $19.76 Mil
  • GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for BIFRF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.68
Price
$31.34
GF Value